About this course
Proprotein convertase subtilisin/kexin type 9 serine protease (PCSK9) is an enzyme that regulates low density
lipoprotein (LDL) receptor degradation. The gene for PCSK9 is implicated in patients with familial
hypercholesterolemia, and a gain-of-function mutation in that gene was found to be associated with high
LDL-cholesterol (LDL-C) levels.
PCSK9 inhibitors are monoclonal antibodies that prevent the degradation of LDL receptors thereby decreasing
LDL-C levels. This e-learning module discusses the biology behind PCSK9, the mechanism of PCSK9 inhibitors,
and when to use PCSK9 inhibitors for lipid-lowering management.
Upon completion of the educational activity, participants should be able to:
- Understand the role of PCSK9 in cholesterol metabolism and the mechanism of action of PCSK9 inhibitors
- Review the data behind drugs acting on PCSK9
- Enumerate the uses of PCSK9 inhibitors in current guidelines
- Biochemistry of PCSK9
- Drugs acting on PCSK9
- Review of Outcomes Trials of PCSK9 inhibitors & siRNA
- Current recommendations for use of PCSK9 inhibitors & siRNA
Speaker for this course:
DR. Dick C.Y. Cheung
Specialist in Cardiology
Keywords: dyslipidemia, PCSK9, PCSK9 inhibitors, when to use PCSK9 inhibitors
1 CME Point Available
- This module is accredited for 1 CME Point for medical practitioners enrolled in The Medical Council
Hong Kong’s Continuing Medical Education Programme for Practising Doctors who are not taking CME
This module is accredited for both Hong Kong Doctors Union (HKDU) members and non-members.
- This module is accredited for 0.5 CME Point for fellows of the Hong Kong College of Physicians, Hong Kong College of Emergency Medicine, and Hong Kong College of Community Medicine.
- Please note that this module will not earn CME credit for fellows of colleges not
- A certificate can be downloaded upon successful completion of the quiz. Please use the information
the certificate to claim your CME points.